Medivir AB (MVIRb.F): Marketing Authorization Application for Simeprevir to the European Medicines Agency for the Treatment of Patients With Genotype 1 and Genotype 4 Hepatitis C is Now Filed
4/24/2013 11:43:39 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX: MVIR) (STO:MVIR-B) today announces that Janssen-Cilag International NV (Janssen) today has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) seeking approval for simeprevir (TMC435). ”The filing of simeprevir in Europe represents the third filing in major regions in the last two months. It shows the commitment and speed with which our partner Janssen acts in the process of bringing new hepatitis C treatments to the market”, said Maris Hartmanis, CEO of Medivir AB.
Help employers find you! Check out all the jobs and post your resume.
comments powered by